Page last updated: 2024-09-04

canertinib and Melanoma

canertinib has been researched along with Melanoma in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berwick, M; Ho, J; Khan, A; Kirkwood, JM; Lee, JY; Ng, YK; Siegfried, JM; Stabile, LP; Supko, KM; Torres, SM	1
Abdiu, A; Djerf Severinsson, EA; Gréen, H; Hallbeck, AL; Stål, O; Trinks, C; Walz, TM	1

Other Studies

2 other study(ies) available for canertinib and Melanoma

Article	Year
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma research, 2014, Volume: 24, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Humans; Indoles; Inhibitory Concentration 50; Ligands; Melanoma; Molecular Targeted Therapy; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Sulfonamides; Vemurafenib	2014
The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. Biochemical and biophysical research communications, 2011, Oct-28, Volume: 414, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; Humans; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptor, ErbB-3; STAT3 Transcription Factor	2011

Article

Year

Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment.

Melanoma research, 2014, Volume: 24, Issue:3

Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Humans; Indoles; Inhibitory Concentration 50; Ligands; Melanoma; Molecular Targeted Therapy; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Skin Neoplasms; Sulfonamides; Vemurafenib

2014

The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo.

Biochemical and biophysical research communications, 2011, Oct-28, Volume: 414, Issue:3

Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Female; Humans; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptor, ErbB-3; STAT3 Transcription Factor

2011